Carregant...
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic regimen for use of each agent beyond the second line for patients with mCRC remains unclear and various factors may influence tre...
Guardat en:
| Publicat a: | ESMO Open |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555611/ https://ncbi.nlm.nih.gov/pubmed/31231561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000495 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|